Business
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary
About this update from Esperion Therapeutics, Inc.
[{"type":"text","content":"– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia – – Bempedoic Acid Receives Equal Positioning with PCSK9 mAb and Ezetimibe After Statins for High-Risk Primary Prevention and Clinical ASCVD Not at Very High-Risk Patients – – Guideline Recognition of Early Combination Lipid-Lowering Therapy and Reintroduction of LDL-C Goals Affirms ‘Lower for Longer is Better’ Approach to Cardiovascular Risk Reduction – ANN ARBOR, Mich., March 16, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid for LDL-C lowering and cardiovascular risk reduction in the 2026 Americal College of Cardiology (ACC)/American Heart Association (AHA) Multisociety Guideline on the Management of Dyslipidemia. “The reintroduction of guideline-directed LDL-C targets to reduce cumulative LDL-C exposure emphasizes the importance of earlier, aggressive combination therapy and the acknowledgement of statin intolerance as a significant clinical challenge to reducing cardiovascular risk addresses a critical unmet need,” said Christie Ballantyne, MD, Professor of Medicine and Chief of Cardiology and Cardiovascular Research at Baylor College of Medicine. “These guidelines provide practical, evidence-based recommendations on how and when to escalate therapy beyond statins to more effectively reduce risk and improve long-term cardiovascular outcomes for patients.” “Recognition from the preeminent American cardiovascular medical associations marks a significant milestone for patients, clinicians and Esperion,” said Sheldon Koenig, President and CEO of Esperion. “The multiple Class 1 recommendations for bempedoic acid underscore its validation as a rigorously studied, evidence-based therapy for patients who require additional LDL-C lowering or who are unable to tolerate statins. This level of endorsement strengthens our position within the treatment landscape and will play an essential role in accelerating adoption and expanding access to NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe).” Summary of Key Bempedoic Acid Guideline Recommendations Class of Recommendation 1: In adults without a history of clinical atherosclerotic cardiovascular disease (ASCVD) who experience ...